Comparison of Dopamine and Norepinephrine in the Treatment of Shock
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Both dopamine and norepinephrine are recommended as first-line vasopressor agents in the treatment of shock. There is a continuing controversy about whether one agent is superior to the other. METHODS: In this multicenter, randomized trial, we assigned patients with shock to receive either dopamine or norepinephrine as first-line vasopressor therapy to restore and maintain blood pressure. When blood pressure could not be maintained with a dose of 20 microg per kilogram of body weight per minute for dopamine or a dose of 0.19 microg per kilogram per minute for norepinephrine, open-label norepinephrine, epinephrine, or vasopressin could be added. The primary outcome was the rate of death at 28 days after randomization; secondary end points included the number of days without need for organ support and the occurrence of adverse events. RESULTS: The trial included 1679 patients, of whom 858 were assigned to dopamine and 821 to norepinephrine. The baseline characteristics of the groups were similar. There was no significant between-group difference in the rate of death at 28 days (52.5% in the dopamine group and 48.5% in the norepinephrine group; odds ratio with dopamine, 1.17; 95% confidence interval, 0.97 to 1.42; P=0.10). However, there were more arrhythmic events among the patients treated with dopamine than among those treated with norepinephrine (207 events [24.1%] vs. 102 events [12.4%], P<0.001). A subgroup analysis showed that dopamine, as compared with norepinephrine, was associated with an increased rate of death at 28 days among the 280 patients with cardiogenic shock but not among the 1044 patients with septic shock or the 263 with hypovolemic shock (P=0.03 for cardiogenic shock, P=0.19 for septic shock, and P=0.84 for hypovolemic shock, in Kaplan-Meier analyses). CONCLUSIONS: Although there was no significant difference in the rate of death between patients with shock who were treated with dopamine as the first-line vasopressor agent and those who were treated with norepinephrine, the use of dopamine was associated with a greater number of adverse events. (ClinicalTrials.gov number, NCT00314704.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dopamine (DA) is a neurotransmitter in the catechol family, which is often used as first-line vasoactive drug in patients with septic shock (43).”
From Dopamine Is a Siderophore-Like Iron Chelator That Promotes Salmonella enterica Serovar Typhimurium Virulence in Mice (2019) · cites this paper as [43]
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Self-citationWriting Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationCDC definitions for nosocomial infections, 1988
Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., & Hughes, J. M. (1988) · American Journal of Infection Control · doi:10.1016/0196-6553(88)90053-3 · Cited by 5,672
CDC definitions for nosocomial infections
Yangco, B. G. (1989) · American Journal of Infection Control · doi:10.1016/s0196-6553(89)80013-6 · Cited by 3,770
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Treating Patients with Severe Sepsis
Wheeler, A. P., & Bernard, G. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400307 · Cited by 992
Current Epidemiology of Septic Shock: The CUB-Réa Network
Annane, D., Aegerter, P., Jars-Guincestre, M. C., & Guidet, B. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2201087 · Cited by 637
Research works printed but not linked: 1
- Mullner M, 2004, Cochrane Database Syst Rev, 3, CD003709
Cited by
Items 501–600 of 1,000
Hospital Patterns of Use of Positive Inotropic Agents in Patients With Heart Failure
Partovian, C., Gleim, S., Mody, P. S., Li, S., Wang, H., Strait, K. M., Allen, L. A., Lagu, T. C., Normand, S. T., & Krumholz, H. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.011 · Cited by 32
“Data on the comparative effectiveness of these agents on the outcomes of patients with heart failure are lacking (5).”
BackgroundMøller, M. H., Granholm, A., Junttila, E., Haney, M., Oscarsson‐Tibblin, A., Haavind, A., Laake, J. H., Wilkman, E., Sverrisson, K., & Perner, A. (2018) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.13089 · Cited by 32
“use dopamine rather than dobutamine in this population, they do so in the context of high-quality RCTs, given the harm associated with use of dopamine in patients with septic shock(17,18) and in a subgroup analysis of patients with cardiogenic shock in the SOAP 2 trial.(39) Importantly, adequate fluid resuscitation sh…”
BackgroundMethodInfluentialIdentifying cardiogenic shock in the emergency department
Daly, M., Long, B., Koyfman, A., & Lentz, S. A. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.09.045 · Cited by 32
“Norepinephrine is associated with less arrhythmias than dopamine [60] and is the vasopressor of choice for initial stabilization of shock [8,9,56,61].”
The medical treatment of cardiogenic shock: cardiovascular drugs
Backer, D. D., Ortiz, J. A., & Lévy, B. (2021) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000822 · Cited by 32
“In the subgroup of 280 patients with cardiogenic shock, dopamine was associated with a significant increase in mortality [15].”
BackgroundHow We Escalate Vasopressor and Corticosteroid Therapy in Patients With Septic Shock
Teja, B. J., Bosch, N. A., & Walkey, A. J. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.09.019 · Cited by 33
Norepinephrine Dosing in Obese and Nonobese Patients With Septic Shock
Radosevich, J. J., Patanwala, A. E., & Erstad, B. L. (2016) · American Journal of Critical Care · doi:10.4037/ajcc2016667 · Cited by 32
Noradrenaline in preterm infants with cardiovascular compromise
Rowcliff, K., de Waal, K., Abdellatif, M., & Chaudhari, T. (2016) · European Journal of Pediatrics · doi:10.1007/s00431-016-2794-7 · Cited by 32
Lee, E., Hsia, S., Lin, J., Chan, O., Lee, J., Lin, C.-Y., & Wu, H. (2017) · BioMed Research International · doi:10.1155/2017/3613475 · Cited by 32
“Circulatory shock causes mortality in children and accounts for one-third of cases in intensive care units (ICUs) [1, 2].”
BackgroundInfluentialManagement of Cardiogenic Shock in a Cardiac Intensive Care Unit
Kim, J. H., Sunkara, A., & Varnado, S. (2020) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-16-1-36 · Cited by 32
An outlook on biomarkers in cardiogenic shock
Egea, O. I., Montero, S., & Bayés‐Genís, A. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000739 · Cited by 32
“Some studies also suggest using troponins to evaluate the systemic repercussions of cardiogenic shock, its causes, and comorbidities [13].”
BackgroundHemodynamic management of acute kidney injury
Backer, D. D., Rimachi, R., & Duranteau, J. (2024) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001213 · Cited by 31
Ultrasonic evaluation of the heart
Backer, D. D. (2014) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000094 · Cited by 31
“Shock is associated with mortality rates around 50% [1,2] and requires prompt therapy, aiming at not only controlling its source but also supporting the hemodynamics [3].”
BackgroundHemodynamic Monitoring and Support
Vincent, J., Joosten, A., & Saugel, B. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005213 · Cited by 31
Self-citationHua, F., Wang, X., & Zhu, L. (2012) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2012.02.073 · Cited by 31
Review article: the role of the microcirculation in liver cirrhosis
Davies, T., Wythe, S., O’Beirne, J. P., Martín, D., & Gilbert-Kawai, E. T. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14279 · Cited by 31
“At the tail end of the oxygen cascade, and ultimately regulating tissue blood flow to match micro-regional oxygen demand, lies the largest “organ” in the body—the microcirculation.(11) Anatomically it consists of a network of blood vessels less than 100 lm in diameter”
BackgroundAn overview of international cardiogenic shock guidelines and application in clinical practice
van Diepen, S., & Thiele, H. (2019) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000624 · Cited by 31
ST-Segment Elevation Myocardial Infarction
Antman, E. M., & Morrow, D. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00055-x · Cited by 31
Neue KDIGO-Leitlinien zur akuten Nierenschädigung: Praktische Handlungsempfehlungen
Zarbock, A., John, S., Jörres, A., & Kindgen‐Milles, D. (2014) · Der Anaesthesist · doi:10.1007/s00101-014-2344-5 · Cited by 31
Acute kidney injury in cardiogenic shock: A comprehensive review
Sheikh, O., Nguyen, T., Bansal, S., & Prasad, A. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29141 · Cited by 30
“De Backer et al in the SOAP II trial conducted one of the largest multicenter randomized control trials (RCT) comparing dopamine and norepinephrine for the treatment of shock.(36) This study examined the efficacy of pressor support in multiple types of shock including in CS.”
MethodHemodynamic support in septic shock
García-de-Acilu, M., Mesquida, J., Gruartmoner, G., & Ferrer, R. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000959 · Cited by 30
“Less adverse events have been observed from noradrenaline than other agents such as dopamine [50], epinephrine, and phenylephrine [51,52].”
BackgroundVasopressor and Inotrope Use in Canadian Emergency Departments: Evidence Based Consensus Guidelines
Djogovic, D., MacDonald, S., Wensel, A., Green, R., Loubani, O. M., Archambault, P. M., Bordeleau, S., Messenger, D. W., Szulewski, A., Davidow, J., et al. (2015) · Canadian Journal of Emergency Medicine · doi:10.1017/cem.2014.77 · Cited by 30
“17 This systematic review found that dopamine increased mortality at 28 days (RR 1.12; 95% CI 1.01 – 1.20; p = .035).”
InfluentialCardiopulmonary monitoring of shock
Simmons, J. A. T., & Ventetuolo, C. E. (2017) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000407 · Cited by 30
“com distributive shock was most common (64%), followed by hypovolemic (16%), cardiogenic (15%), and obstructive (2%) shock among all comers with circulatory failure [2].”
BackgroundKotecha, A. A., Vallabhajosyula, S., Apala, D. R., Frazee, E., & Iyer, V. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618768180 · Cited by 30
“Similar to the Sepsis Occurrence in Acute Ill Patients trial, the greater incidence of AKI and cardiac arrhythmias in this study could be related to the use of greater epinephrine in patients with normal weight and morbidly obese patients compared to underweight patients.(29) Even though epinephrine did not demonstrat…”
ResultSaudi Heart Association (SHA) guidelines for the management of heart failure
AlHabeeb, W., Alayoubi, F., Alghalayini, K. W., Ghofaili, F. A., Hebaishi, Y. A., Al‐Jazairi, A. S., Al-Mallah, M. H., Almasood, A. S., Qaseer, M. A., AlSaif, S. M., et al. (2019) · Journal of the Saudi Heart Association · doi:10.1016/j.jsha.2019.06.004 · Cited by 30
“001) [187], and thus is the preferred vasopressor.”
BackgroundFeistritzer, H., Desch, S., Zeymer, U., Fuernau, G. F., de Waha‐Thiele, S., Dudek, D., Huber, K., Stępińska, J., Schneider, S., Ouarrak, T., et al. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.118.007661 · Cited by 30
Shah, P. M., & Cowger, J. A. (2014) · Critical Care Clinics · doi:10.1016/j.ccc.2014.03.001 · Cited by 30
“appears to offer a less favorable short-term mortality when compared with norepinephrine.(87) In 280 patients with CS managed with vasopressor support, dopamine was associated with increased tachyarrhythmias and mortality compared with norepinephrine.”
Pathophysiologic Vasodilation in Cardiogenic Shock and Its Impact on Mortality
Chavez, M. A., Anderson, M., Kyriakopoulos, C. P., Scott, M., Dranow, E., Maneta, E., Hamouche, R., Taleb, I., Leon, J., Kogelschatz, B., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011827 · Cited by 29
“17,18 Finally, we defined a blunted pressor response, a novel metric, as those patients with a low SVR 800 dsc-5 on any dose of pressors or patients with a normal SVR of 800 to 1200 despite a high norepinephrine equivalent dose > 0.2 µg/kg per minute.”
InfluentialVincent, J., & Annoni, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237372 · Cited by 29
Self-citationWentowski, C. C., Mewada, N., & Nielsen, N. D. (2018) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2018.11.009 · Cited by 29
Management of Vasoplegic Shock in the Cardiovascular Intensive Care Unit after Cardiac Surgery
Suero, O. R., Park, Y., Wieruszewski, P. M., & Chatterjee, S. (2023) · Critical Care Clinics · doi:10.1016/j.ccc.2023.06.002 · Cited by 29
The Management of Cardiogenic Shock From Diagnosis to Devices
Alkhunaizi, F. A., Smith, N., Brusca, S. B., & Furfaro, D. M. (2024) · CHEST Critical Care · doi:10.1016/j.chstcc.2024.100071 · Cited by 29
“62 However, no singular approach exists, and often norepinephrine is used concurrently with the inodilator dobutamine for greater β -agonist effect, or epinephrine can be used as monotherapy.”
BackgroundManagement of Right Heart Failure in the Intensive Care Unit
Kholdani, C. A., & Fares, W. H. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2015.05.015 · Cited by 29
“Compared with NE in the treatment of shock, however, it was associated with more adverse events, particularly tachyarrhythmia, and an increased frequency of death among the subset with cardiogenic shock in a large multicenter, randomized trial.(39)”
Keegan, J. M., & Wira, C. (2014) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2014.07.002 · Cited by 29
Colling, K. P., Banton, K. L., & Beilman, G. J. (2018) · Surgical Infections · doi:10.1089/sur.2017.255 · Cited by 29
“Following these reports, The Sepsis Occurrence in Acutely Ill Patients (SOAP II) group performed a multicenter randomized study directly comparing DA and NE in patients with shock [23].”
Emergency Neurological Life Support: Traumatic Spine Injury
Stein, D. M., Pineda, J., Roddy, V., & Knight, W. A. (2015) · Neurocritical Care · doi:10.1007/s12028-015-0169-y · Cited by 29
Norepinephrine as a First-Line Inopressor in Cardiogenic Shock
van Diepen, S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.052 · Cited by 29
“The selection of norepinephrine as an active comparator is appropriate and likely stems from the SOAP (Sepsis Occurrence in Acutely Ill Patients) II trial, which is the largest and most rigorously conducted trial of inopressor therapies in patients with any form of shock (12).”
BackgroundInotropic therapies in heart failure and cardiogenic shock: an educational review
DesJardin, J. T., & Teerlink, J. R. (2021) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuab047 · Cited by 28
“myocardial infarction.(20) Major guidelines recommend against use of dopamine in acute myocardial infarction.”
BackgroundBauer, S. R., Sacha, G. L., Siuba, M., Lam, S. W., Reddy, A. J., Duggal, A., & Vachharajani, V. (2022) · Critical Care Explorations · doi:10.1097/cce.0000000000000634 · Cited by 28
Ródenas‐Alesina, E., Scolari, F. L., Wang, V. N., Brahmbhatt, D. H., Mihajlovic, V., Fung, N. L., Otsuki, M., Billia, F., Overgaard, C. B., & Luk, A. C. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14379 · Cited by 28
“nerstone therapies in the management of CS, although data are limited with respect to clinical outcomes.(7,9,10) While ob-”
BackgroundManagement of Sepsis: A 47-Year-Old Woman With an Indwelling Intravenous Catheter and Sepsis
Angus, D. C. (2011) · JAMA · doi:10.1001/jama.2011.438 · Cited by 30
Management of Right Heart Failure in the Critically Ill
King, C. S., May, C. W., Williams, J. D., & Shlobin, O. A. (2014) · Critical Care Clinics · doi:10.1016/j.ccc.2014.03.003 · Cited by 28
Intensive Care Unit Management of Patients with Liver Failure
Siddiqui, M. S., & Stravitz, R. T. (2014) · Clinics in Liver Disease · doi:10.1016/j.cld.2014.07.012 · Cited by 28
Aletti, F. M., Conti, C., Ferrario, M., Ribas, V. J., Pinto, B. B., Herpain, A., Post, E. H., Medina, E. R., Barlassina, C., de Oliveira, E., et al. (2016) · Scandinavian Journal of Trauma Resuscitation and Emergency Medicine · doi:10.1186/s13049-016-0197-4 · Cited by 28
“They convey instantaneous information on the CV status of the patient, but they cannot accurately predict the occurrence of hypotensive episodes and are often not sufficient to guide a timely and effective Early Goal Directed Therapy [20–22], because of the poor understanding of the pathological cascades characterizin…”
BackgroundCritical care ultrasonography in circulatory shock
Koster, G., & van der Horst, I. C. C. (2017) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000428 · Cited by 28
“A large randomized trial found septic shock (as the most common form of distributive shock) in 62% of the patients, followed by cardiogenic and hypovolemic shock (both 16%), other types of distributive shock in 4%, and obstructive shock in 2% of the patients [4].”
BackgroundWen, L., & Xu, L. (2020) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-019-0768-x · Cited by 28
Continuous cardiac output assessment or serial echocardiography during septic shock resuscitation?
Vignon, P. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.04.11 · Cited by 28
“in intensive care unit (ICU) patients (1).”
(2012) · Kidney International Supplements · doi:10.1038/kisup.2011.38 · Cited by 28
Sepsis in the Pediatric Cardiac Intensive Care Unit: An Updated Review
Babu, S., Sreedhar, R., Munaf, M., & Gadhinglajkar, S. V. (2023) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2023.02.011 · Cited by 27
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Acute Medicine & Surgery · doi:10.1002/ams2.70037 · Cited by 27
Hiemstra, B., Eck, R. J., Koster, G., Wetterslev, J., Perner, A., Pettilä, V., Snieder, H., Hummel, Y. M., Wiersema, R., de Smet, A. M. G. A., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017170 · Cited by 27
“These patients have an increased risk of multiorgan failure, long-term morbidity and mortality.(2) 3 A recent consensus statement on circulatory shock recommends to use a combination of clinical, biochemical and/or haemodynamic variables, varying from simple to advanced, for establishing the diagnosis and instigation…”
BackgroundJentzer, J. C., Herrmann, J., Prasad, A., Barsness, G. W., & Bell, M. R. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.01.245 · Cited by 27
“Norepinephrine appears to have a more favorable safety profile than either dopamine or epinephrine when used for vasopressor support in patients with shock (59,60).”
BackgroundNorepinephrine Use in Cardiogenic Shock Patients is Associated with Increased 30 Day Mortality
Lu, X., Wang, X., Gao, Y., Walline, J. H., Yu, S., Ge, Z., Qin, M., Zhu, H., & Li, Y. W. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13893 · Cited by 27
“Comparing norepinephrine and dopamine use in diverse causes of shock, a large RCT including 1679 patients showed that norepinephrine was associated with decreased 28 day mortality in the subgroup of 280 patients in cardiogenic shock.(8) In our study containing data between 2001 to 2012, dopamine was used in 45 to 50%…”
BackgroundResultInfluentialLaw, A. C., Bosch, N. A., Peterson, D., & Walkey, A. J. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.04.147 · Cited by 27
Gupta, S., Mandal, S., Banerjee, K., Almarshood, H., Pushpakumar, S. B., & Sen, U. (2024) · Biomolecules · doi:10.3390/biom14091165 · Cited by 27
“The After fl uid therapy or volume resuscitation, a vas-opressor drug should be given to ensure enough renal perfusion to prevent a positive fl uid balance [334,342–344]. recommended first-line vasopressor in a vasodilatory state is noradrenaline [345,346].”
MethodMortara, A., Oliva, F. G., Metra, M., Carbonieri, E., Lenarda, A. D., Gorini, M., Midi, P., Senni, M., Urso, R., Lucci, D., et al. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.05.015 · Cited by 27
Management of cardiogenic shock complicating acute myocardial infarction
Herck, J. L., Claeys, M. J., Paep, R. D., Herck, P. L. V., Vrints, C. J., & Jorens, P. G. (2015) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872614568294 · Cited by 27
Cardiogenic shock: Inotropes and vasopressors
Amado, J., Gago, P., Santos, W., Mimoso, J., & de Jesus, I. (2016) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2016.08.004 · Cited by 27
“The drug with the greatest impact on mortality in patients with shock is norepinephrine.(26)”
BackgroundRecent developments in the management of patients resuscitated from cardiac arrest
Jentzer, J. C., Clements, C. M., Murphy, J. G., & Wright, R. S. (2017) · Journal of Critical Care · doi:10.1016/j.jcrc.2017.02.011 · Cited by 27
“patients with shock and in patients with septic shock [10,84,89,90].”
BackgroundDavidsen, C., Packer, E. J. S., Løland, K. H., Rotevatn, S., Nygreen, E. L., Eriksen, E., Øksnes, A., Herstad, J., Haaverstad, R., Bleie, Ø., et al. (2019) · Resuscitation · doi:10.1016/j.resuscitation.2019.04.022 · Cited by 27
Beyond Mean Arterial Pressure and Lactate: Perfusion End Points for Managing the Shocked Patient
Hallisey, S. D., & Greenwood, J. C. (2019) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2019.03.005 · Cited by 27
Advanced airway management and respiratory care in decompensated pulmonary hypertension
Vahdatpour, C., Ryan, J. J., Zimmerman, J., MacCormick, S., Palevsky, H. I., Alnuaimat, H., & Ataya, A. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10168-9 · Cited by 27
Red blood cell transfusion during septic shock in the ICU
Perner, A., Smith, S. H., Carlsen, S., & Holst, L. B. (2012) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2012.02666.x · Cited by 27
“01 mg/ kg/min noradrenaline.(11) The converted dose of dopamine was added to any noradrenaline dose and referred to as the maximum vasopressor dose.”
MethodSantschi, M., & Leclerc, F. (2013) · Annals of Intensive Care · doi:10.1186/2110-5820-3-7 · Cited by 27
Polyak, P., Kwak, J., Kertai, M. D., Anton, J. M., Assaad, S. I., DaCosta, M., Dimitrova, G. T., Gao, W. D., Henderson, R. A., Hollon, M., et al. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.02.047 · Cited by 26
Tarasawa, K., Fujimori, K., & Fushimi, K. (2020) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.252.53 · Cited by 26
“…Tazobactam/Piperacillin, New Quinolone) (Ely et al. 2018); use of catecholamines (i.e., Noradrenaline, Adrenaline, Dopamine, Dobutamine) (De Backer et al. 2010); blood transfusion (i.e., Red blood cells, Platelets) (Park et al. 2012); Mechanical ventilator (Iwagami et al. 2014);…”
BackgroundBlood pressure deficits in acute kidney injury: not all about the mean arterial pressure?
Forni, L. G., & Joannidis, M. (2017) · Critical Care · doi:10.1186/s13054-017-1683-4 · Cited by 26
“may have a role in norepinephrine refractory shock [3, 4].”
BackgroundRodriguez, R. W., Cucci, M. D., Kane, S. P., Fernandez, E. M., & Benken, S. T. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618818460 · Cited by 26
“Catecholamine vasopressors carry significant risks, including tachyarrhythmias, worsening organ function, myocardial injury, elevation of serum lactate, hyperglycemia, and limb ischemia.5-9 Additionally, treatment with catecholamine and inotropic agents are independent predictors for developing arrhythmias, which carr…”
BackgroundInfluentialTherapeutic Advances in the Management of Cardiogenic Shock
Chioncel, O. D., Collins, S. P., Ambrosy, A. P., Pang, P. S., Radu, R. I., Antohi, E., Masip, J., Butler, J., & Iliescu, V. A. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000920 · Cited by 26
Filho, R. R., Chaves, R. C. D. F., de Assunção, M. S. C., Neto, A. S., Freitas, F. M. D., Romagnoli, M. L., Silva, E., Lattanzio, B., Dubín, A., & Corrêa, T. D. (2019) · Journal of Clinical Monitoring and Computing · doi:10.1007/s10877-019-00423-8 · Cited by 26
“eral perfusion parameters has not been incorporated into routine clinical practice so far [11, 12].”
BackgroundExtracorporeal Membrane Oxygenation—Understanding the Evidence: CESAR and Beyond
Sidebotham, D. A. (2011) · Journal of ExtraCorporeal Technology · doi:10.1051/ject/201143p23 · Cited by 26
“Nevertheless, it is possible that some of these treatments studied (dopamine (20), high-dose renal replacement therapy (21), intensive glucose control (22), albumin fluid therapy (23), or corticosteroids (24)) do impact (positively or negatively) mortality in appropriately selected patients.”
BackgroundAssociation Between Vasopressin Rebranding and Utilization in Patients With Septic Shock*
Sacha, G. L., Kiser, T. H., Wright, G. C., Vandivier, R. W., Moss, M., Burnham, E. L., Ho, P. M., Reynolds, P., & Bauer, S. R. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005305 · Cited by 25
Pharmacological treatment of cardiogenic shock – A state of the art review
Bruno, R. R., Wolff, G., Kelm, M., & Jung, C. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108230 · Cited by 25
Fármacos vasoactivos en el tratamiento del shock séptico
Andaluz‐Ojeda, D., Cantón‐Bulnes, M. L., Richter, C. P., & Garnacho‐Montero, J. (2022) · Medicina Intensiva · doi:10.1016/j.medin.2022.03.001 · Cited by 26
Neonatal septic shock, a focus on first line interventions.
Spaggiari, V., Passini, E., Crestani, S., Roversi, M. F., Bedetti, L., Rossi, K., Lucaccioni, L., Baraldi, C., Muttini, E. D. C., Lugli, L., et al. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93i3.12577 · Cited by 25
Cardiac Syndromes in Liver Disease: A Clinical Conundrum
Branković, M., Lee, P. C., Pyrsopoulos, N., & Klapholz, M. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00294 · Cited by 25
Early Recognition and Risk Stratification in Cardiogenic Shock: Well Begun Is Half Done
Polyzogopoulou, E., Bezati, S., Karamasis, G. V., Boultadakis, A., & Parissis, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072643 · Cited by 25
The rise and fall of drotrecogin alfa (activated)
Vincent, J. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70175-5 · Cited by 25
Self-citationIs it time for permissive hypoxaemia in the intensive care unit?
Capellier, G., & Panwar, R. (2011) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01625-3 · Cited by 25
Nunnally, M. (2016) · British Journal of Anaesthesia · doi:10.1093/bja/aew333 · Cited by 25
“Dopamine is no longer routinely recommended because of the potential for dysrhythmias.(39) 40 Although the exact role for endocrine replacement is unclear, evidence suggests that vasopressin and glucocorticoids can be helpful in some instances.”
BackgroundFawzy, A., & Walkey, A. J. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002409 · Cited by 25
Multidisciplinary Management of the Post–Cardiac Arrest Patient
Madder, R. D., & Reynolds, J. C. (2017) · Cardiology Clinics · doi:10.1016/j.ccl.2017.08.005 · Cited by 25
Varol, T. Ö., Birel, Ö., & Anık, Ü. (2018) · Analytical Letters · doi:10.1080/00032719.2017.1388816 · Cited by 25
“Dopamine is commonly used as a medication for the initial emergency treatment of hypotension and alternative treatment of bradycardia (Freeman and Natanson 2000; De Backer et al. 2010).”
BackgroundFluid Resuscitation for Refractory Hypotension
Valverde, A. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.621696 · Cited by 25
The Unmet Need for Addressing Cardiac Issues in Intensive Care Research*
van Diepen, S., Granger, C. B., Jacka, M. J., Gilchrist, I. C., Morrow, D. A., & Katz, J. N. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000609 · Cited by 25
Novel insights in endocrine and metabolic pathways in sepsis and gaps for future research
Téblick, A., Gunst, J., Langouche, L., & den Berghe, G. V. (2022) · Clinical Science · doi:10.1042/cs20211003 · Cited by 24
Bernard, S., Deferm, S., & Bertrand, P. B. (2022) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuac086 · Cited by 24
The principles and conduct of anaesthesia for emergency surgery
Gray, L. D., & Morris, C. (2012) · Anaesthesia · doi:10.1111/anae.12057 · Cited by 24
“[150] SOAP II Study Comparison of haemodynamic therapy noradrenaline vs dopamine No significant difference mortality Higher rates tachyarrythmias with dopamine and excess mortality in cardiogenic shock Morris and Gray | Principles and conduct of anaesthesia for emergency surgery Anaesthesia 2013, 68 (Suppl.”
BackgroundSepsis: Update in the Management
Venkataraman, R., & Kellum, J. A. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.10.013 · Cited by 24
“A recent RCT demonstrated no survival difference between patients with shock who were treated with dopamine as the first-line vasopressor agent and those who were treated with norepinephrine.(31) However, the use of dopamine was associated with increased adverse events in this study.”
BackgroundVela, J. L. P., Benitez, J. C. M., González, M. C., López, M. Á. D. L. C., Pérez, R. H., Meneses, V. S., & Sáez, F. D. N. (2012) · Medicina Intensiva · doi:10.1016/j.medin.2012.01.016 · Cited by 24
Zhao, M., Kong, L., & Qu, H. (2014) · Scientific Reports · doi:10.1038/srep04176 · Cited by 24
“Norepinephrine plays a critical role in decision making and can affect attention; it is also used as anti-depressant and anti-schizophrenic 38,39 .”
BackgroundTerao, Y., Ichinomiya, T., Higashijima, U., Tanise, T., Miura, K., Fukusaki, M., & Sumikawa, K. (2011) · Journal of Anesthesia · doi:10.1007/s00540-011-1300-7 · Cited by 24
Vasopressors and Inotropes in the Treatment of Human Septic Shock: Effect on Innate Immunity?
Hartemink, K. J., & Groeneveld, A. B. J. (2011) · Inflammation · doi:10.1007/s10753-011-9306-8 · Cited by 24
“In the study by De Backer, norepinephrine- and dopamine-treated patients had similar mortality, but adverse events were more frequent with the latter [29].”
BackgroundSepsis: A Review for the Neurohospitalist
Karnatovskaia, L. V., & Festić, E. (2012) · The Neurohospitalist · doi:10.1177/1941874412453338 · Cited by 24
“However, in a subsequently published trial of 1679 patients randomized to norepinephrine versus dopamine, a subgroup analysis showed that dopamine was associated with an increased rate of death at 28 days among the 280 participants with cardiogenic shock.(37) A recent review of 6 trials comparing the 2 agents confirme…”
Hodge, E. K., Hughes, D. W., & Attridge, R. L. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016656384 · Cited by 24
“Finally, the lack of correlation between change in MAP at 1 hour and increasing vasopressin dose in relation to weight observed in our study may partially be attributed to the high severity of illness, estimated by the APACHE II score, seen in our patient population when compared with previous studies.(15,19)”
ResultPareek, N., Kordis, P., Webb, I. G., Noč, M., MacCarthy, P. A., & Byrne, J. (2019) · Interventional Cardiology Reviews Research Resources · doi:10.15420/icr.2019.3.2 · Cited by 24
Management of Acute Heart Failure during an Early Phase
Takagi, K., Kimmoun, A., Sato, N., & Mebazaa, A. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0014 · Cited by 24
Differential effects of inotropes and inodilators on renal function in acute cardiac care
Zima, E., Farmakis, D. T., Pollesello, P., & Parissis, J. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa091 · Cited by 24
“SOAP investigators also demonstrated a deleterious effect of dopamine on mortality and rate of new-onset arrhythmias in cardiogenic shock patients.(27) Brief reference may be made here to fenoldopam, a D1receptor agonist, for which no strong case can bemade.”
BackgroundInotrope and vasopressor use in cardiogenic shock: what, when and why?
Hu, K., & Mathew, R. (2022) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000957 · Cited by 24
“finding increased arrhythmias and 28-day mortality with dopamine compared to norepinephrine in the SOAP II trial [28].”
BackgroundPulmonary Hypertension in Intensive Care Units: An Updated Review.
Nowroozpoor, A., Malekmohammad, M., Seyyedi, S. R., & Hashemian, S. M. R. (2019) · PubMed Central · Cited by 24
Gonzales, X. F., Castillo-Rojas, G., Castillo-Rodal, A. I., TUOMANEN, E. I., & López‐Vidal, Y. (2013) · Microbiology · doi:10.1099/mic.0.065607-0 · Cited by 24
Metadata
- Authors
- De Backer, D., Biston, P., Devriendt, J., Madl, C., Chochrad, D., Aldecoa, C., Brasseur, A., Defrance, P., Gottignies, P., & Vincent, J.-L.
- Affiliations
- Université Libre de Bruxelles (BE)
- Medical University of Vienna (AT)
- Centre hospitalier Etterbeek-Ixelles (BE)
- Erasmus Hospital (BE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-03-04
- Volume
- 362
- Issue
- 9
- Pages
- 779-789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095944485
- Cited by
- 1,940
- References
- 31
- Citations by year
- 2026: 98 · 2025: 107 · 2024: 140 · 2023: 115 · 2022: 125 · 2021: 132 · 2020: 135 · 2019: 138 · 2018: 106 · 2017: 139 · 2016: 99 · 2015: 122 · 2014: 120 · 2013: 96 · 2012: 110
- FWCI
- 83.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Hemodynamic Monitoring and Therapy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Trauma, Hemostasis, Coagulopathy, Resuscitation
- Keywords
- dopamine, norepinephrine, vasopressors, shock, cardiogenic shock, septic shock, hypovolemic shock, 28-day mortality, cardiac arrhythmias, epinephrine, vasopressin, organ support, adverse events, subgroup analysis, vasopressor weaning
- MeSH terms
- Aged, Arrhythmias, Cardiac, Combined Modality Therapy, Dopamine, Female, Fluid Therapy, Humans, Male, Middle Aged, Norepinephrine, Shock, Vasoconstrictor Agents, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.